Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven G Potkin

Showing results (21-30 of 217) with videos related to

Pageof 22
Sort By:
Journal of Clinical Psychopharmacology|May 6, 2008
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studiesSteven G Potkin, Robert E Litman, Rosarelis Torres, et al.
Journal of Clinical Psychopharmacology|July 14, 2005
Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trialSteven G Potkin, Paul E Keck, Scott Segal, et al.
The Journal of Clinical Psychiatry|July 4, 2009
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophreniaSimona Volpi, Steven G Potkin, Anil K Malhotra, et al.
The Journal of Clinical Psychiatry|May 21, 2003
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophreniaPeter J Weiden, George M Simpson, Steven G Potkin, et al.
The Journal of Clinical Psychiatry|August 3, 2010
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJohn M Kane, Steven G Potkin, David G Daniel, et al.
American Journal of Alzheimer'S Disease and Other Dementias|December 20, 2003
Memory for emotional stimuli in patients with Alzheimer's diseaseKirsten Fleming, Susan H Kim, Michael Doo, et al.
The International Journal of Neuropsychopharmacology|December 8, 2004
Gender: a major determinant of brain response to nicotineJames H Fallon, David B Keator, James Mbogori, et al.
Schizophrenia Research|October 1, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysisSteven G Potkin, Phillip Phiri, Armin Szegedi, et al.
Brain Research. Cognitive Brain Research|January 23, 2004
Hostility differentiates the brain metabolic effects of nicotineJames H Fallon, David B Keator, James Mbogori, et al.
The International Journal of Neuroscience|July 25, 2006
Alpha EEG predicts visual reaction timeYi Jin, James P O'Halloran, Lawrence Plon, et al.
Pageof 22

Showing results (21-30 of 217) with videos related to

Sort By:
Pageof 22
Journal of Clinical Psychopharmacology|May 6, 2008
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studiesSteven G Potkin, Robert E Litman, Rosarelis Torres, et al.
Journal of Clinical Psychopharmacology|July 14, 2005
Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trialSteven G Potkin, Paul E Keck, Scott Segal, et al.
The Journal of Clinical Psychiatry|July 4, 2009
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophreniaSimona Volpi, Steven G Potkin, Anil K Malhotra, et al.
The Journal of Clinical Psychiatry|May 21, 2003
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophreniaPeter J Weiden, George M Simpson, Steven G Potkin, et al.
The Journal of Clinical Psychiatry|August 3, 2010
A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophreniaJohn M Kane, Steven G Potkin, David G Daniel, et al.
American Journal of Alzheimer'S Disease and Other Dementias|December 20, 2003
Memory for emotional stimuli in patients with Alzheimer's diseaseKirsten Fleming, Susan H Kim, Michael Doo, et al.
The International Journal of Neuropsychopharmacology|December 8, 2004
Gender: a major determinant of brain response to nicotineJames H Fallon, David B Keator, James Mbogori, et al.
Schizophrenia Research|October 1, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysisSteven G Potkin, Phillip Phiri, Armin Szegedi, et al.
Brain Research. Cognitive Brain Research|January 23, 2004
Hostility differentiates the brain metabolic effects of nicotineJames H Fallon, David B Keator, James Mbogori, et al.
The International Journal of Neuroscience|July 25, 2006
Alpha EEG predicts visual reaction timeYi Jin, James P O'Halloran, Lawrence Plon, et al.
Pageof 22